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ReviewAutoimmunity through Cytokine-Induced
Dendritic Cell Activation
from the studies demonstrating induction of autoimmu-
nity during IFN- therapy (Ronnblom et al., 1991) and
existence of circulating inducers of IFN- in SLE pa-
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3434 Live Oak tients’ blood (Vallin et al., 1999).
Independent observations by several groups in theDallas, Texas 75204
late 90s to early 00s led us to propose that SLE might
indeed be due to a break in peripheral tolerance due to
activation of myeloid dendritic cells (DCs) in responseWe propose a model where autoimmunity can be
viewed as a dynamic system driven by opposite vec- to an excess of IFN- (Blanco et al., 2001). These mile-
stones included the demonstration of (1) the critical roletors IFN-/ and TNF. These cytokines drive differenti-
ation of distinct types of DCs, TNF-DCs, or IFN-DCs, of immature DCs in the maintenance of peripheral toler-
ance (Steinman et al., 2003) that contrast with the abilitywhich present different antigens leading to distinct
autoimmune responses. When balanced, both cyto- of mature DCs to induce antigen-specific immunity (re-
viewed in Banchereau and Steinman, 1998; Banchereaukines synergize in protective immunity. When one of
the cytokines prevails, autoimmunity occurs, Type I et al., 2000; Lanzavecchia and Sallusto, 2001), (2) the
remarkable capacity of plasmacytoid DCs (pDCs) to se-interferons (IFN-/) playing a major role in systemic
lupus erythematosus (SLE) and TNF playing a major crete large amounts of IFN- upon exposure to viruses
(Cella et al., 1999; Siegal et al., 1999) as well as bacterialrole in rheumatoid arthritis. This model complements
the Type 1/Type 2 paradigm. Therefore, immunity can DNA (Bauer et al., 2001; Krug et al., 2001), and (3) the
ability of IFN- to activate immature myeloid DCs (Luftbe viewed as a dynamic system driven by two sets of
opposite vectors: IFN-//TNF and IFN-/IL-4. et al., 1998; Paquette et al., 1998; Santini et al., 2000;
Blanco et al., 2001).
Historical Perspective
The immune system evolved to protect us from mi- Dendritic Cells
crobes. The antigen (Ag)-nonspecific innate immunity T and B cells are under the control of DCs (Steinman
and Ag-specific adaptive immunity (Fearon and Locks- 1991; Banchereau and Steinman, 1998; Banchereau et
ley, 1996; Medzhitov and Janeway, 1997) synergize to al., 2000; Shortman and Liu, 2002), which thereby control
eradicate the invading pathogen through cells, such as immunity and tolerance (reviewed in Turley, 2002;
dendritic cells (DCs) and lymphocytes, and through their Moser, 2003; Steinman et al., 2003). The first 25 years
effector proteins, including antimicrobial peptides, com- of DC research mostly focused on how they turn on
plement, and antibodies (reviewed in Palucka and immunity, particularly following microbial encounter. Im-
Banchereau, 2002). Its intrinsic complexity renders the mature, antigen-capturing mDCs sitting in peripheral
system prone to dysfunction, including cancer, autoim- tissues sense pathogens, tissue necrosis, and local in-
munity, chronic inflammation, and allergy. flammation. These signals induce DCs to undergo a
Immune cells use cytokines to communicate with maturation process while migrating through the afferent
each other. Cytokines, most particularly TNF (Feldmann lymphatics into the T cell areas of draining lymph nodes.
and Maini, 2001) and Type I interferon, are regarded as There, they present processed Ags to T cells via both
essential factors in the development of autoimmunity. classical (MHC class I and class II) and nonclassical
Identification of TNF as a major factor in the pathogene- (CD1 family) antigen-presenting molecules (Banchereau
sis of rheumatoid arthritis and the development of anti- et al., 2000). This results in T cell proliferation and differ-
TNF therapy represent a success of immunology. Rec- entiation into helper and effector cells with unique func-
ognition of this success is demonstrated by the year tion and cytokine profiles. DCs also activate B cells, NK
2003 Lasker Award being given to Drs. Feldman and cells, and NK T cells. Mature, antigen-loaded DCs are
Maini, pioneers of this field. Yet, it took more than two geared toward the launching of antigen-specific immu-
decades to understand the liaison between systemic nity (Finkelman et al., 1996) though recent data indicate
lupus erythematosus (SLE) and Type I interferon that mature DCs also activate regulatory T cells. Imma-
(IFN-). In 1979, Notkins et al. reported the presence ture (nonactivated) DCs capture and present self-anti-
of interferon activity in the serum of patients suffering gens (e.g., apoptotic cells) to T cells (Albert et al., 1998a;
from autoimmune diseases, including SLE, arthritis, and Albert et al., 1998b; Heath and Carbone, 2001), which
scleroderma (Hooks et al., 1979). The findings were sub- in the absence of appropriate costimulation leads to
sequently confirmed mainly in SLE (Preble et al., 1982; tolerance. How this complex balance is maintained in
von Wussow et al., 1988). The nature of circulating IFN health and broken in autoimmunity is now starting to
has however represented a puzzle, as it was found to be understood.
react with antibodies to Type I IFN yet it was acid labile, In early 90s, culture systems were discovered that
a property usually ascribed to IFN- (Preble et al., 1982). produced large amounts of mouse (Inaba et al., 1992)
Further confirmation of the role of IFN- in SLE came and human DCs, thereby accelerating their characteriza-
tion (Caux et al., 1992; Romani et al., 1994; Sallusto
and Lanzavecchia, 1994). Two major DC pathways are*Correspondence: jacquesb@baylorhealth.edu (J.B.); virginip@
baylorhealth.edu (V.P.) thought to exist (reviewed in Banchereau et al., 2000;
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Shortman and Liu, 2002): (1) a myeloid pathway, which conditions, tolerance can be induced to an ongoing au-
toimmune disease, such as EAE, a model system forgenerates at least two subsets, including Langerhans
cells (LCs), found in stratified epithelia such as skin; and multiple sclerosis (M. Nussenzweig, personal communi-
cation). In contrast, a concomitant activation with anti-interstitial DCs (intDCs), found in all other tissues. These
subsets display common and unique functions. Thus, CD40 results in the mounting of a potent immune re-
sponse, as DCs are induced to express a large numberwhile both subsets can produce IL-12 and induce naive
CD4 T cell proliferation, only interstitial DCs produce of costimulatory molecules (Bonifaz et al., 2004).
In vivo induction of tolerance to apoptotic cell compo-IL-10 and can induce the differentiation of naive B cells
into immunoglobulin-secreting plasma cells (Caux et al., nents include a burst of T cell proliferation followed by
their subsequent deletion. The capture and processing1996, 1997). Another pathway (2) includes plasmacytoid
DCs (pDCs), which secrete, upon viral encounter, within of cell-associated antigens in the periphery has been
documented with the proton pump ATPase of the gastrica few hours large amounts of Type I interferon (Cella et
al., 1999; Siegal et al., 1999). Therefore, pDCs represent parietal cells (Scheinecker et al., 2002). During autoim-
mune gastritis induced by thymectomy, the number ofa first barrier to the expansion of intruding viruses, thus
acting as member of the innate immunity. Importantly, antigen-containing DCs increase in the draining node
as well as the antigen-presenting function of these DCsthese cells subsequently differentiate into DCs able to
induce immune responses, thus acting as members of (Scheinecker et al., 2002). Selective deletion of DCs us-
ing specific toxins (Jung et al., 2002) was found to avoidadaptive immunity (Kadowaki et al., 2000). Thus, differ-
ent DC subsets control different effector pathways of the depletion of antigen-specific T cells by antigen-
loaded dying splenocytes. Such tolerance mechanismsthe immune system.
permit to prevent or reduce the development of autoim-
munity when dying cells are generated and processedDendritic Cells and Tolerance
at the time of infection (Liu et al., 2002).Central Tolerance
It can thus be easily imagined that “inappropriate”The thymus steadily produces thymocytes expressing
activation of what should otherwise be an immature,newly assembled TCR, some of which may be reactive
tolerogenic DC may lead to the break of peripheral toler-with components of self. High-affinity autoreactive thy-
ance and launch immunity to self-antigens.mocytes are eliminated upon encountering self-MHC
peptide (Marrack and Kappler, 1997; Sprent and Kishi-
moto, 2002; Starr et al., 2003). There is evidence that
Unique Alterations in Systemic Lupusboth thymic epithelial cells as well as mature DCs in the
Erythematosus Bloodthymus may be involved in this process (Brocker, 1999;
Systemic lupus erythematosus (SLE) is a prototype au-Fujimoto et al., 2002). The high frequency of circulating
toimmune disease characterized by a break of toleranceautoreactive T cells in the nonautoimmune repertoire
to nuclear components and profound alterations of theindicates that central tolerance mechanisms are not suf-
immune system (Desai-Mehta et al., 1996; Marrack etficient to purge newly made T cells from their autoreac-
al., 2001; Shlomchik et al., 2001; Wakeland et al., 2001).tive elements. Therefore, autoreactive T cells that are
SLE Patients Display Considerable Lymphopenianot deleted in the thymus need to be controlled in the
SLE patients display considerable lymphopenia that af-periphery to prevent immune responses to self. This is
fects both T cell and B cell compartments. The B cellcollectively described as peripheral tolerance.
compartment presents several unusual features (Oden-Peripheral Tolerance through DCs
dahl et al., 2000; Arce et al., 2001; Lipsky 2001). ThereThere is now evidence that immature DCs play an impor-
is a major decrease in the frequency and numbers oftant role in peripheral tolerance (Steinman et al., 2003).
both naive and memory B cells. In contrast, pregerminalImmature DCs within peripheral tissues capture cells
center cells that express CD38 are found in increaseddying by apoptosis and migrate through the lymphatics
frequency but not increased numbers (Arce et al., 2001).to the draining lymph node. These cells actually consti-
Plasmablasts, however, represent a significant fractiontute the long recognized afferent flux of veiled cells
of the B cell pool, as their numbers are increased 3-fold(Pugh and MacPherson, 1982). Indeed, DCs loaded with
when compared to healthy age-matched individualsapoptotic material are found in the steady-state within
(Odendahl et al., 2000; Arce et al., 2001). T cells are alsolymph nodes, draining tissues, such as the intestinal
decreased in numbers and appear to react differentlyepithelium (Huang et al., 2000), the airway (Vermaelen
from normal cells, as they are more resistant to activa-et al., 2001), and the skin. Once they reach draining
tion (Tsokos et al., 2003). Importantly, SLE CD8 T cellslymph nodes, immature DCs present self-peptide-MHC
appear to express higher levels of granzymes, and theircomplexes, in the absence of costimulation signals, to
number correlates with disease severity (P. Blanco, per-the circulating naive autoreactive T cells. This results in
sonal communication). Overexpression of effector mole-their inactivation either by anergy or deletion. Immature
cules involved in cell lysis may not be restricted to CD8DCs may also control peripheral tolerance through in-
T cells, as CD4 T cells from patients with active SLEduction and maintenance of regulatory T cells (Cobbold
show perforin overexpression as well (Kaplan et al.,and Waldmann, 1998; Roncarolo et al., 2001; Sakaguchi
2004). Such enhanced activity of cytotoxic lymphocyteset al., 2001; Shevach et al., 2001; Bluestone and Abbas,
could be targeted against autologous cells (for example,2003). The groups of M. Nussenzweig and R. Steinman
monocytes; Kaplan et al., 2004) and may contribute thehave elegantly shown that fusion proteins targeted to
source of autoantigens (Casciola-Rosen et al., 1994,DCs lead to antigen-specific tolerance induction when
DCs are left immature (Bonifaz et al., 2002). Under these 1999).
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Figure 1. Fate of Autoreactive T Cells
Autoreactive thymic escapees are silenced in
periphery via immature DCs, which control
peripheral tolerance. Excess IFN- induces
unabated DC maturation, which leads to acti-
vation/expansion of autoreactive T cells.
DCs Numbers Are Reduced in SLE Blood these cells are able to induce the proliferation of allore-
active T cells, a property characteristic of DCs (BlancoMyeloid DCs (mDCs), characterized as CD14CD11hi
HLA-DRcells, are reduced by about 30% in the blood of et al., 2001). It is generally accepted that DCs do not
express CD14 because the blood CD11c mDCs andSLE patients, which is barely significant. Plasmacytoid
DCs (pDCs), characterized as CD123hi, HLA-DRlo, and the DCs generated in vitro with a combination of GM-
CSF and IL-4 do not express CD14. Yet, DCs made byLinneg, are reduced by as much as 70% (Blanco et al.,
2001; Gill et al., 2002). This is consistent with the early culturing monocytes with a combination of GM-CSF and
IFN (Santini et al., 2000) or GM-CSF and IL-15 (Moha-description of reduced numbers of IFN--producing
cells in SLE blood in response to DNA-anti-DNA immune madzadeh et al., 2001) do express CD14. Indeed, incu-
bation of monocytes from healthy individuals with serumcomplexes (Cederblad et al., 1998). This reduction in
numbers is not solely due to the effect of medication, from active SLE patients results in the generation of
CD14 cells with certain characteristics of DCs, includ-as the blood was analyzed at the time of diagnosis,
before treatment initiation. This is an important consid- ing phenotype and ability to induce an MLR. Neutralizing
anti-IFN- have demonstrated IFN- to be the keyeration, as steroids, a classic treatment of SLE, can
reduce the number of pDCs to nearly zero when adminis- SLE serum factor responsible for the differentiation of
monocytes into DCs. Furthermore, normal serum spikedtered at high dose (Shodell et al., 2003).
SLE Monocytes Act as DCs with recombinant IFN- can also induce the differentia-
tion of monocytes into DCs. SLE serum contains otherCD14 blood cells are normally immunologically quies-
cent monocytes that are unable to mount the so-called cytokines that may participate in the DC-induction ef-
fect. In particular, high levels of CD40 ligand are foundmixed lymphocyte reaction (MLR). However, in SLE
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(Desai-Mehta et al., 1996; Kato et al., 1999; Vakkalanka
et al., 1999) and increased levels of FLT-3L correlate
with disease severity (Gill et al., 2002). These IFN-driven
DCs capture apoptotic cells and present their antigens
to T cells (Blanco et al., 2001). Indeed, SLE may be
viewed as a problem in the processing of apoptotic cells
by DCs (Bellone et al., 1997) rather than by macrophages
(Fadok et al., 1992; Baumann et al., 2002).
IFN- Signature in SLE
The quantitation of IFN in SLE serum can be performed
by ELISA or using antiviral bioassays. In all cases, only
Figure 2. IFN- as a Pathogenic Factor in SLEa fraction of the patients display detectable circulating
High levels of IFN- in SLE might explain several immunologicalIFN-. Yet, microarray analysis of blood mononuclear
findings of this disease, including (1) permanent maturation of my-cells demonstrates that the vast majority of patients we
eloid DCs resulting in activation rather then silencing of autoreactivehave analyzed to date (68/70 children and 11/11 adults)
T cells and autoantigen presentation from captured apoptotic cells;
display an IFN signature (Baechler et al., 2003; Bennett (2) T lymphopenia (Lin et al., 1998), concomitant with expansion of
et al., 2003). In addition to the IFN- signature, another effector T cells overexpressing granzymes and perforin; and (3) B
unique signature, that of immature granulocytes, could lymphopenia (Lin et al., 1998), concomitant with the expansion of
CD38 GC-like B cells (Galibert et al., 1996) found in SLE blood andbe found in most of the patients suffering from the most
accelerated plasma cell differentiation.severe form of the disease (Bennett et al., 2003). Interest-
ingly, an antimicrobial peptide (defensin DEFA-3) was
among the genes that correlate best with disease activ-
induce B cell growth and differentiation (Dubois et al.,ity. As defensins have been shown to activate DCs (Bira-
1997, 1998; Fayette et al., 1997; Litinskiy et al., 2002).gyn et al., 2002), their overexpression may add to the
Several molecules have been shown to be involved inoverall DC activation in SLE. The typical SLE PBMCs
this process, including IL-12, IL-6 (Banchereau et al.,signature cannot be found in other autoimmune dis-
2000), and, more recently, BAFF/Blys (Schneider et al.,eases tested to date, including the various kinds of juve-
1999; Batten et al., 2000; Gross et al., 2000; Balazs etnile idiopathic arthritis. Importantly, the SLE signature
al., 2002; MacLennan and Vinuesa, 2002), a moleculediffers from that found in patients acutely suffering from
upregulated by IFN-, which overexpression of in miceviral infections like influenza virus or herpes virus (our
induces lupus-like syndrome (Mackay et al., 1999). Fur-unpublished data) though an IFN- signature can also
thermore, immature neutrophils might represent a con-be found in these patients’ PBMCs.
siderable source of Blys (Scapini et al., 2003) thus con-
tributing to altered B cell homeostasis in SLE.pDCs Drive Plasma Cell Differentiation
through IFN-
SLE has long been thought of as an alteration of the B Systemic Lupus Erythematosus
as an IFN--Driven Diseasecell compartment with increased generation of plasma
cells and production of autoantibodies (Shlomchik et SLE is a remitting disease characterized by flares that
progressively result in deterioration of the patient. Theseal., 2001). Given the central role of IFN- in SLE, the
question arises as to whether IFN-might be responsi- flares are often associated to viral infections. The infec-
tion in SLE, which might represent a primary element inble for the increased frequency of plasma cells in this
disease (Jego et al., 2003). Indeed, activated B cells disease development, triggers unabated production of
IFN-. This increased bioavailability of IFN- inducesexposed to IFN- differentiate into CD38hi CD20neg
plasmablasts that do not secrete much immunoglobu- and maintains the generation of mature DCs. The in-
crease of mature DCs and decrease of immature DCslins (Jego et al., 2003). However, upon exposure to IL-6,
another pDC product, the IFN--generated plas- therefore tilts the fate of autoreactive T lymphocytes
from deletion to activation. Indeed, tissue turnover per-mablasts, differentiates into highly efficient Ig-secreting
plasma cells. Activated B cells exposed to virus-trig- manently generates apoptotic cells, which are captured
by immature DCs. These cells present apoptotic cell-gered pDCs differentiate into efficient Ig-secreting
plasma cells in both IFN-- and IL-6-dependent man- derived antigens, including nuclear antigens, to autore-
active T cells in a manner that results in their silencing/ner. Strikingly, the plasma cells generated under these
conditions express very high levels of CD38, similar to deletion. In contrast, mature DCs, which are induced in
SLE by IFN-, will activate and expand these T cells.that of plasma cells isolated from lymphoid tissues. In
contrast, plasma cells generated by culturing activated Thus, a high-affinity autoreactive T cell that exits from
the thymus will eventually be activated and expandedB cells with the T cell-derived cytokines IL-2 and IL-10,
though efficient Ig secretors, do not express high levels (Figure 1). This creates a first autoimmune injury, which
might then be amplified by a vicious circle of self-antigenof CD38 (Arpin et al., 1995). This suggests that IFN-
may represent an important cytokine in the generation capture and presentation by IFN-DCs (Figure 2).
Several scenarios could be contemplated to explainof tissular plasma cells. Indeed, studies in the mouse
have also found that IFN- is an excellent adjuvant for the break of B cell tolerance and generation of anti-DNA
antibodies. (1) IFN-DCs would present autoantigens tohumoral immunity (Le Bon et al., 2001). However, there
may also be an indirect contribution of IFN- to plasma CD4 T cells and the expanded autoreactive T cells would
help differentiation of autoantibody-producing B cells,cell differentiation because activated myeloid DCs can
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Figure 3. Mechanisms of Excess IFN-
Virus triggers IFN- secretion that normally is controlled by SOCS1 and/or by TNF. Continued presence of TLR7 or TLR9 ligands, for example,
virus, or DNA-anti-DNA immune complexes, sustains IFN- production, which is further supported by deletion of SOCS1 function (through
genetic alteration) and/or by TNF blockade via soluble TNF receptors.
in a classical me´nage a trois (Banchereau and Steinman, viewing the pDC as a main producer of IFN- (Cella et
1998). (2) B cells are activated in a T cell-independent al., 1999; Siegal et al., 1999; Kadowaki et al., 2000; As-
fashion, through combined B cell receptor and TLRs selin-Paturel et al., 2001). Indeed, while pDCs are signifi-
engagement, for example, with chromatin-containing cantly decreased in the SLE blood (Blanco et al., 2001;
immune complexes (Leadbetter et al., 2002; Viglianti et Gill et al., 2002), they accumulate in the skin at the site
al., 2003). Indeed, the majority (55%–75%) of all antibod- of the typical SLE rashes (Blomberg et al., 2001; Farkas
ies expressed by early immature B cells from healthy et al., 2001). This is where they might produce the IFN-
individuals display self-reactivity, including polyreactiv- in excess, as the microarray analysis did not reveal in-
ity and antinuclear specificities (Wardemann et al., creased transcription of IFN molecules in SLE blood
2003). While these self-specificities are normally re- (Bennett et al., 2003). Other cell types may however
moved from the repertoire at discrete checkpoints dur- contribute to the excessive IFN- production. For in-
ing B cell development (Wardemann et al., 2003), IFN stance, IFN- triggers TLR7 expression on monocytes
alone and/or IFN-DCs could alter these checkpoints and and DCs, which can be induced to produce IFN- in
allow the differentiation of some of these autoreactive response to TLR7 agonists (Mohty et al., 2003), such as
clones into fully secreting plasma cells. Indeed, there is virus-derived single-stranded RNA (Diebold et al., 2004;
evidence that DCs can present antigens directly to B Heil et al., 2004). Mechanisms that may lead to IFN-
cells (Wykes et al., 1998; Macpherson and Uhr, 2004) oversecretion include: (1) genetic alterations that result
and induce their maturation and isotype switch (Dubois in unabated secretion of IFN-. The alteration may be
et al., 1997, 1998; Fayette et al., 1997; Litinskiy et al., within the IFN secretion mechanism, as exemplified by
2002). The ensuing immune complexes would then am- SLE in SOCS-1/ mice (Hanada et al., 2003). (2) The
plify and perpetuate the above described B cell activa- increased levels of soluble TNF receptors in SLE serum,
tion loop. This, however, may not explain the initiation
which may contribute to sustained IFN production by
of the disease before anti-DNA antibodies are made
blocking TNF, which by itself shuts down the production
(Arbuckle et al., 2003). (3) SLE patients may display ge-
of IFN, as discussed later. (3) The presence of immunenetically imprinted alterations in the autoreactive B cell
complexes containing either RNA or DNA, which,checkpoints that are independent from IFN and DCs
through triggering of TLR-7 and 9, respectively, mayand would allow the survival of autoreactive clones into
sustain IFN production by pDCs (Bave et al., 2001). In-the peripheral compartment. IFN and/or IFN-DC would
deed, the development of SLE is believed to require ajust contribute to the activation and differentiation of
combination of environmental, e.g., viruses, and geneticthese clones into autoantibody-secreting plasma cells.
alterations. Our recent studies in mice demonstrate thatIn favor of this last possibility, healthy relatives of SLE
sustained administration of low levels of IFN- can dra-patients often display antinuclear antibodies. Similarly,
matically precipitate the onset of the disease in NZB/WB6.Sle1 congenic mice display intrinsic B cell alterations
F1 while leaving normal mice unaffected (A. Mathian, S.that lead to the development of anti-chromatin antibod-
Koutouzov, and J.B., unpublished data). Furthermore,ies in the absence of T cell help. In spite of the high
crossing both NZB and B6 lpr/lpr mice with a Type I IFNautoantibody titers, these mice do not develop further
receptor KO strain significantly decreases morbidity andSLE manifestations (Sobel et al., 2002).
prolongs mouse survival (Braun et al., 2003; Kono etA critical point that remains to be clarified is the mech-
al., 2003; Santiago-Raber et al., 2003). Taken together,anism leading to unabated production of IFN- in SLE
these data also demonstrate the importance of IFN-(Figure 3). IFN- can be produced by many cell types
(Biron et al., 1999; Katze et al., 2002), many currently in mouse models of SLE.
Immunity
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Figure 4. The Weight of Cytokine Environment on DC Differentiation/Maturation
Microbes can induce DC maturation directly via pattern recognition receptors on DCs. Alternatively, other cell types, including stromal cells
(epithelial cells, keratinocytes, and fibroblasts), mast cells, plasmacytoid DCs, and NK cells respond to microbes by secreting different
cytokines (IFN-/, TNF, IFN-, IL-4, IL-15, IL-1, etc.). Such cytokines activated DC differentially yielding distinct subsets that induce distinct
types of immune responses.
Crossregulation of TNF and IFN- benefit from replacement therapy with recombinant TNF
(Jacob and McDevitt, 1988).in Autoimmune Diseases
It is now well accepted that TNF plays a critical role in On the other side of the spectrum, there is evidence
that IFN-/ may regulate TNF. For example, TNF ispathogenesis of autoimmune diseases, such as rheuma-
toid arthritis (Feldmann and Maini, 2001) and psoriasis implicated in the pathogenesis of multiple sclerosis
(Hofman et al., 1989; Selmaj et al., 1991) and is involved(Gottlieb, 2003). Accordingly, TNF antagonists have
proven to be efficient therapy of RA (Feldmann and in EAE, an experimental model for multiple sclerosis.
IFN- knockout mice seem more susceptible to EAEMaini, 2001) and psoriasis (Leonardi et al., 2003). How-
ever, these antagonists may lead to clinical complica- than the wild-type (Teige et al., 2003), and administration
of IFN- to mice with EAE inhibits disease progressiontions, such as reactivation of tuberculosis (Gomez-Reino
et al., 2003) and reversible SLE (reviewed in Reimold, (Yu et al., 1996). In humans, IFN- can inhibit in vitro TNF
production by microglia, either directly or by attenuating2002; Ehlers, 2003). Conversely, anti-TNF therapy is not
effective in patients with SLE and may in fact worsen the ability of T cells to trigger TNF secretion by microglial
cells (Chabot et al., 1997). This regulatory mechanismclinical symptoms of this disease. These clinical obser-
vations suggest that TNF might regulate IFN- produc- might partially explain the beneficial effect of IFN- ther-
apy in this disease (Chabot et al., 1997). Furthermore,tion. Indeed, TNF inhibts IFN- release by pDCs ex-
posed to influenza virus and completely blocks pDCs PBMCs from healthy volunteers injected with IFN-
show markedly decreased secretion of TNF and lympho-generation from CD34 hematopoietic progenitors (our
unpublished data). Conversely, TNF antagonists en- toxin as compared to placebo-treated volunteers (Ro-
thuizen et al., 1999).hance the production of IFN-/ by pDCs exposed
in vitro to viruses. Furthermore, treatment of patients Taken together, our data open a new way to look at
the control of autoreactive immune responses, whichsuffering from systemic onset juvenile idiopathic arthritis
with anti-TNF induces overexpression of IFN--regu- have been challenging to integrate within the Th1/Th2
paradigm (Mosmann and Coffman, 1989; Romagnani,lated genes in blood leukocytes (our unpublished data).
These results may thus provide a mechanistic explana- 1995). We therefore propose to extend this paradigm
and integrate two antagonistic paths, i.e., the IFN pathtion for the increased anti-dsDNA antibodies and lupus-
like syndrome in a fraction of patients treated with TNF and the TNF path. These paths lead to contrasting im-
mune responses, which might yield opposite patholo-antagonists. Conversely, high levels of soluble TNF re-
ceptors in SLE (Gattorno et al., 1998; Davas et al., 1999; gies, i.e., lupus and arthritis (Figure 4).
Gill et al., 2002) may block endogenous TNF. The TNF-
mediated downregulation of the Type I interferon path- Different Cytokines Generate Different DCs that May
Lead to Different Autoimmune Syndromesway could also explain earlier observations in the mouse
lupus model NZB/W, which bear a genetic deficiency In response to microbial infection, cells from the invaded
tissue secrete different cytokines. The cytokines mayof TNF (Jacob et al., 1990). Consequently, these mice
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Figure 5. Distinct DC Subsets Induce Different Autoimmune Response, Leading to Different Autoimmune Diseases
IFN-/ and TNF will generate distinct DC subsets. These DCs will capture opsonized apoptotic bodies. Distinct proteolytic enzymes expressed
by these distinct DC subsets will generate distinct repertoire of peptides leading to a distinct set of MHC peptide complexes and, thus, a
distinct antigen-specific lymphocyte repertoire. IFN-DCs will present nuclear antigens eventually leading to generation of anti-dsDNA antibodies
typical of SLE. In contrast, TNF-DCs will present Fc fragment of immunoglobulins eventually leading to generation of rheumatoid factor typical
of rheumatoid arthritis.
differ for several reasons: (1) they may originate from they will yield IL4-DCs (Peters et al., 1993; Romani et
al., 1994; Sallusto and Lanzavecchia, 1994). Upon en-different cells (e.g., keratinocytes, fibroblasts, or mast
cells) (Benoist and Mathis, 2002) or (2) the same cell counter with IFN- or TNF, they will differentiate into
IFN-DCs (Luft et al., 1998; Paquette et al., 1998; Santinimay secrete different cytokines in response to different
microbial components. These cytokines will induce at- et al., 2000; Blanco et al., 2001) or TNF-DCs (Chomarat
et al., 2003), respectively (Figure 4). Each DC subsettracted monocytes to differentiate into either macro-
phages that can digest and destroy the microbes or displays common as well as unique biological functions
determined by a unique combination of cell surface mol-DCs that will permit the launching of specific immune
responses (Banchereau and Steinman, 1998; Randolph ecules and cytokines. Indeed, while IL-4 DCs represent
a homogenous population of cells devoid of Langerhanset al., 1999; Banchereau et al., 2000; Chomarat et al.,
2000, 2003). The different cytokines that may be pro- cells, TNF-DCs are heterogeneous and include both
CD1a Langerhans cells and CD14 interstitial DCsduced skew the differentiation of monocytes into differ-
ent DCs. For example, when monocytes encounter IL-4, (Chomarat et al., 2003). The latter subsets differ in their
Figure 6. The Four Arms of Immune Homeo-
stasis and Disease
Immunity is viewed as a dynamic system
driven by two sets of opposite vectors, i.e.,
TNF and IFN-/, IL-4 and IFN-. The sum of
the vectors yields an equilibrium point, which
allows protective immunity when vectors are
equal. This dynamic system can accommo-
date a prevalence of either vector. However,
when one of the vectors prevails beyond a
certain threshold, the equilibrium point moves
into a zone of autoimmunity. Thus, when TNF
vector prevails, then TNF-mediated autoim-
munity will occur, such as arthritis. When
IFN-/ vector prevails, then IFN autoimmu-
nity will occur, including SLE, thyroiditis, and
diabetes. The prevalence of IL-4 will drive al-
lergy while IFN- will sustain inflammation.
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